MAP2K7 and melanoma: The discovery of constitutive activity of the BRAF-MEK-ERK signalling pathway in melanomagenesis emphasizes the importance of these signalling pathway intermediates as potential therapeutic targets in treating melanoma especially those that have become resistant to BRAFV600E inhibitors.